Form 8-K - Current report:
SEC Accession No. 0001213900-25-046909
Filing Date
2025-05-22
Accepted
2025-05-22 17:10:57
Documents
14
Period of Report
2025-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0243287-8k_onconetix.htm   iXBRL 8-K 31296
2 NOTE, DATED MAY 16, 2025 ea024328701ex10-1_onconetix.htm EX-10.1 28407
3 PRESS RELEASE DATED MAY 22, 2025 ea024328701ex99-1_onconetix.htm EX-99.1 7365
  Complete submission text file 0001213900-25-046909.txt   249825

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20250516.xsd EX-101.SCH 3041
5 XBRL LABEL FILE onco-20250516_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE onco-20250516_pre.xml EX-101.PRE 22376
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0243287-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 25978222
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)